CN107106544B - 用于治疗脑转移瘤的方法 - Google Patents

用于治疗脑转移瘤的方法 Download PDF

Info

Publication number
CN107106544B
CN107106544B CN201580063121.3A CN201580063121A CN107106544B CN 107106544 B CN107106544 B CN 107106544B CN 201580063121 A CN201580063121 A CN 201580063121A CN 107106544 B CN107106544 B CN 107106544B
Authority
CN
China
Prior art keywords
cancer
inhibitor
gap junction
subject
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580063121.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN107106544A (zh
Inventor
J·马萨格
A·博伊尔
Q·陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CN107106544A publication Critical patent/CN107106544A/zh
Application granted granted Critical
Publication of CN107106544B publication Critical patent/CN107106544B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
CN201580063121.3A 2014-09-19 2015-09-18 用于治疗脑转移瘤的方法 Active CN107106544B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052966P 2014-09-19 2014-09-19
US62/052,966 2014-09-19
PCT/US2015/051057 WO2016044790A1 (en) 2014-09-19 2015-09-18 Methods for treating brain metastasis

Publications (2)

Publication Number Publication Date
CN107106544A CN107106544A (zh) 2017-08-29
CN107106544B true CN107106544B (zh) 2021-09-24

Family

ID=55533931

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580063121.3A Active CN107106544B (zh) 2014-09-19 2015-09-18 用于治疗脑转移瘤的方法

Country Status (7)

Country Link
US (3) US10413522B2 (enExample)
EP (2) EP3685832B1 (enExample)
JP (1) JP6898848B2 (enExample)
CN (1) CN107106544B (enExample)
AU (3) AU2015317330B2 (enExample)
CA (1) CA2961894C (enExample)
WO (1) WO2016044790A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106544B (zh) * 2014-09-19 2021-09-24 纪念斯隆-凯特琳癌症中心 用于治疗脑转移瘤的方法
CN107290438B (zh) * 2016-03-31 2020-10-16 深圳翰宇药业股份有限公司 一种多肽有关物质的高效液相色谱分析方法
WO2019014246A1 (en) * 2017-07-10 2019-01-17 Cantley Lewis C TARGETING CHROMOSOMIC INSTABILITY AND SIGNALING OF CYTOSOLIC DNA IN AVAL FOR THE TREATMENT OF CANCER
AU2018314234B2 (en) * 2017-08-11 2024-10-24 Board Of Regents, The University Of Texas System Targeting kinases for the treatment of cancer metastasis
US11717506B2 (en) 2019-05-07 2023-08-08 The Johns Hopkins University Neuroprotective compounds for amyotrophic lateral sclerosis
WO2021051015A1 (en) * 2019-09-13 2021-03-18 Auckland Uniservices Limited Compositions and methods for rescuing retinal and choroidal structure and function
CN111420025B (zh) * 2020-04-28 2021-06-11 中国药科大学 茜草科类型环肽化合物在制备cGAS-STING信号通路激活剂的药物中的应用
GB202014831D0 (en) 2020-09-21 2020-11-04 Dc Europa Ltd Disconnection agents
US12306192B2 (en) * 2021-02-08 2025-05-20 Cedars-Sinai Medical Center Method of detecting cognitive impairment
CN114252324B (zh) * 2022-03-02 2022-05-13 中国人民解放军军事科学院军事医学研究院 一种方便使用的多孔脑片孵育装置
WO2024020491A1 (en) * 2022-07-20 2024-01-25 The University Of North Carolina At Chapel Hill Methods of treating cancer of the central nervous system comprising 5-ethynyl-2'-deoxyuridine
WO2025024284A1 (en) * 2023-07-21 2025-01-30 The Board Of Regents Of The University Of Texas System Monoclonal antibodies against pcdh7 for lung cancer therapy
CN117298143A (zh) * 2023-10-11 2023-12-29 广州医科大学附属第一医院（广州呼吸中心） β葡聚糖在制备治疗肺癌脑转移瘤药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010025272A1 (en) * 2008-08-27 2010-03-04 The Trustees Of Columbia University In The City Of New York Compounds, compositions and methods for reducing toxicity and treating or preventing diseases
WO2014129914A1 (en) * 2013-02-22 2014-08-28 Auckland Uniservices Limited Methods of treatment

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411635D0 (en) 1994-06-10 1994-08-03 Smithkline Beecham Plc Novel treatment
JPH10501256A (ja) 1994-06-10 1998-02-03 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Ｃ−４アミド置換化合物およびその治療剤としての使用
AU740588B2 (en) 1997-11-24 2001-11-08 Scripps Research Institute, The Inhibitors of gap junction communication
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6251931B1 (en) 1998-11-24 2001-06-26 The Scripps Research Institute Inhibitors of gap junction communication
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
US6770633B1 (en) 1999-10-26 2004-08-03 Immusol, Inc. Ribozyme therapy for the treatment of proliferative skin and eye diseases
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
AU2001245793A1 (en) 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
EP1582219A4 (en) 2002-11-29 2007-11-28 Japan Science & Tech Agency CONNEXIN 26 INHIBITORS AND INHIBITORS OF TUMORMETASTASES
KR20060054405A (ko) * 2003-07-31 2006-05-22 더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 암, 암의 발병 또는 암 증상의 치료, 예방 및/또는 개선용조성물 및 방법
ES2766549T3 (es) 2005-02-03 2020-06-12 Coda Therapeutics Ltd Compuestos anticonexina 43 para el tratamiento de heridas crónicas
US7704946B2 (en) 2006-05-05 2010-04-27 Caritas St. Elizabeth's Medical Center Reversible inhibition of pyramidal gap junction activity
CA2710232A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of abnormal or excessive scars
CA2726878A1 (en) * 2008-06-05 2009-12-10 Minster Research Limited Novel treatments
FR2935611B1 (fr) * 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
US20110262442A1 (en) * 2009-11-06 2011-10-27 Adenios, Inc. Compositions for treating cns disorders
AU2010325755A1 (en) 2009-12-03 2012-06-21 Proximagen Ltd Treatment of infectious diseases
JP2013512887A (ja) * 2009-12-03 2013-04-18 プロキシマゲン リミテッド 感染症の治療
CA2908154C (en) * 2013-04-29 2023-11-28 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
EP3057977A4 (en) 2013-10-15 2017-07-26 President and Fellows of Harvard College Methods and compositions for eradicating leukemic cells
CN107106544B (zh) * 2014-09-19 2021-09-24 纪念斯隆-凯特琳癌症中心 用于治疗脑转移瘤的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010025272A1 (en) * 2008-08-27 2010-03-04 The Trustees Of Columbia University In The City Of New York Compounds, compositions and methods for reducing toxicity and treating or preventing diseases
WO2014129914A1 (en) * 2013-02-22 2014-08-28 Auckland Uniservices Limited Methods of treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
cGAMP：一种新的哺乳动物第二信使;郭晓强等;《生物化学与生物物理进展》;20130615;第40卷(第6期);520-523 *

Also Published As

Publication number Publication date
CA2961894A1 (en) 2016-03-24
AU2023219864A1 (en) 2023-09-14
AU2021202257B2 (en) 2023-05-25
JP6898848B2 (ja) 2021-07-07
EP3685832A1 (en) 2020-07-29
US10413522B2 (en) 2019-09-17
AU2021202257A1 (en) 2021-05-06
US20170258758A1 (en) 2017-09-14
AU2015317330A1 (en) 2017-04-13
US11058665B2 (en) 2021-07-13
EP3193865A4 (en) 2018-04-11
JP2017534583A (ja) 2017-11-24
CN107106544A (zh) 2017-08-29
US20220105069A1 (en) 2022-04-07
EP3193865A1 (en) 2017-07-26
WO2016044790A1 (en) 2016-03-24
US12029717B2 (en) 2024-07-09
EP3685832B1 (en) 2023-08-30
NZ730319A (en) 2024-03-22
EP3193865B1 (en) 2019-11-06
US20200085781A1 (en) 2020-03-19
CA2961894C (en) 2023-12-12
AU2015317330B2 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
US12029717B2 (en) Methods for treating brain metastasis
Chen et al. Carcinoma–astrocyte gap junctions promote brain metastasis by cGAMP transfer
Pietrobono et al. ST3GAL1 is a target of the SOX2-GLI1 transcriptional complex and promotes melanoma metastasis through AXL
Camorani et al. Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer
Garcia et al. USP11 Enhances TGFβ-Induced Epithelial–Mesenchymal Plasticity and Human Breast Cancer Metastasis
Hua et al. Peroxisome proliferator-activated receptor gamma as a theragnostic target for mesenchymal-type glioblastoma patients
AU2018202271B2 (en) Agents and methods for treating and preventing seborrheic keratosis
Gentilini et al. CXCR7 contributes to the aggressive phenotype of cholangiocarcinoma cells
Liao et al. GALNT2 promotes invasiveness of colorectal cancer cells partly through AXL
Park et al. Endothelial snail regulates capillary branching morphogenesis via vascular endothelial growth factor receptor 3 expression
WO2017064159A1 (en) Trpv2 as a biomarker and as a therapeutic target for melanoma
Decaudin et al. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy
US20170038384A1 (en) Treatment of tumors expressing mutant p53
Yin et al. Ubiquitin-specific peptidase 15 regulates the TFAP4/PCGF1 axis facilitating liver metastasis of colorectal cancer and cell stemness
US9034327B2 (en) G protein coupled receptor protein and use thereof
Sun et al. circTOP2A functions as a ceRNA to promote glioma progression by upregulating RPN2
Pudelko et al. Increased microtubule growth triggered by microvesicle-mediated paracrine signaling is required for melanoma cancer cell invasion
Fries MicroRNAs as markers to monitor endothelin‐1 signalling and potential treatment in renal disease: Carcinoma− proteinuric damage− toxicity
Li et al. USP28 knockdown and small molecule inhibitors promote KRT1 destabilization and sensitize hepatocellular carcinoma cells to sorafenib
Avinery et al. Hsp70–Bag3 Module Regulates Macrophage Motility and Tumor Infiltration via Transcription Factor LITAF and CSF1. Cancers 2022, 14, 4168
Deng et al. CCN4 shifts melanoma cells from a fragile proliferative state to a resilient metastatic state
Ko ENDOSOMAL PH IS A NOVEL DRIVER OF GLIOBLASTOMA STEMNESS
Aslan Plectin is a regulator of prostate cancer growth and metastasis
Setti SHEDDING LIGHT ON GLIOBLASTOMA AND DERIVED EXTRACELLULAR VESICLES IN ONE CLIC
JP2013040139A (ja) Ｎ−ｍｙｃ下流制御遺伝子１タンパク質を標的とした卵巣明細胞腺癌の治療薬

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant